Measuring health‐related quality of life in MSA: The MSA‐QoL
Identifieur interne : 000976 ( Istex/Curation ); précédent : 000975; suivant : 000977Measuring health‐related quality of life in MSA: The MSA‐QoL
Auteurs : Anette Schrag [Royaume-Uni] ; Caroline Selai [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Philip Low [États-Unis] ; Jeremy Hobart [Royaume-Uni] ; Niall Brady [Royaume-Uni] ; Niall Patrick Quinn [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-12-15.
English descriptors
- KwdEn :
Abstract
The objective of this study was to develop a new patient‐reported outcome measure for patients with multiple system atrophy (MSA) and to test its psychometric properties. There were three stages. First, a pool of potential scale items was generated from in‐depth patient interviews. Second, these items were administered, in the form of a questionnaire, to a sample of people with MSA and traditional psychometric methods used to develop a rating scale satisfying standard criteria for reliability and validity. Third, the psychometric properties of the rating scale were examined in a second sample. In stage one, a pool of 105 items was generated from 20 patient interviews. In stage two, a scale with three subscales (motor, 14 items; nonmotor, 12 items; emotional/social functioning, 14 items), satisfying standard criteria for reliability and validity, was developed from the response data of 317 patients with MSA (response rate 71%). In stage three, the scale was examined in 286 people with MSA. Missing data were low, scores in both subscales were evenly distributed, and floor and ceiling effects were small. Reliability was high (Cronbach's alpha 0.83–0.93; test‐retest ICC 0.88–0.92). Validity was supported by the interscale correlations (r = 0.47–0.59), known group differences, and the magnitude and pattern of correlations with four other rating scales, disease severity, and disease duration. In conclusion, the patient‐rated MSA health‐related Quality of life scale (MSA‐QoL) may be a suitable patient‐reported scale for use in clinical trials and studies in MSA. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21649
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000976
Links to Exploration step
ISTEX:CA7D73FBEAA9D591B85A840BC0BD145CC9A7B991Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Measuring health‐related quality of life in MSA: The MSA‐QoL</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Low, Philip" sort="Low, Philip" uniqKey="Low P" first="Philip" last="Low">Philip Low</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Hobart, Jeremy" sort="Hobart, Jeremy" uniqKey="Hobart J" first="Jeremy" last="Hobart">Jeremy Hobart</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neuroscience, Peninsula Medical School, Plymouth, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neuroscience, Peninsula Medical School, Plymouth</wicri:regionArea></affiliation></author><author><name sortKey="Brady, Niall" sort="Brady, Niall" uniqKey="Brady N" first="Niall" last="Brady">Niall Brady</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall Patrick" sort="Quinn, Niall Patrick" uniqKey="Quinn N" first="Niall Patrick" last="Quinn">Niall Patrick Quinn</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CA7D73FBEAA9D591B85A840BC0BD145CC9A7B991</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21649</idno><idno type="url">https://api.istex.fr/document/CA7D73FBEAA9D591B85A840BC0BD145CC9A7B991/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000976</idno><idno type="wicri:Area/Istex/Curation">000976</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Measuring health‐related quality of life in MSA: The MSA‐QoL</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Low, Philip" sort="Low, Philip" uniqKey="Low P" first="Philip" last="Low">Philip Low</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</wicri:regionArea></affiliation></author><author><name sortKey="Hobart, Jeremy" sort="Hobart, Jeremy" uniqKey="Hobart J" first="Jeremy" last="Hobart">Jeremy Hobart</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neuroscience, Peninsula Medical School, Plymouth, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neuroscience, Peninsula Medical School, Plymouth</wicri:regionArea></affiliation></author><author><name sortKey="Brady, Niall" sort="Brady, Niall" uniqKey="Brady N" first="Niall" last="Brady">Niall Brady</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall Patrick" sort="Quinn, Niall Patrick" uniqKey="Quinn N" first="Niall Patrick" last="Quinn">Niall Patrick Quinn</name><affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15">2007-12-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2332">2332</biblScope><biblScope unit="page" to="2338">2338</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CA7D73FBEAA9D591B85A840BC0BD145CC9A7B991</idno><idno type="DOI">10.1002/mds.21649</idno><idno type="ArticleID">MDS21649</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>development</term><term>multiple system atrophy</term><term>quality of life</term><term>scale</term><term>validation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to develop a new patient‐reported outcome measure for patients with multiple system atrophy (MSA) and to test its psychometric properties. There were three stages. First, a pool of potential scale items was generated from in‐depth patient interviews. Second, these items were administered, in the form of a questionnaire, to a sample of people with MSA and traditional psychometric methods used to develop a rating scale satisfying standard criteria for reliability and validity. Third, the psychometric properties of the rating scale were examined in a second sample. In stage one, a pool of 105 items was generated from 20 patient interviews. In stage two, a scale with three subscales (motor, 14 items; nonmotor, 12 items; emotional/social functioning, 14 items), satisfying standard criteria for reliability and validity, was developed from the response data of 317 patients with MSA (response rate 71%). In stage three, the scale was examined in 286 people with MSA. Missing data were low, scores in both subscales were evenly distributed, and floor and ceiling effects were small. Reliability was high (Cronbach's alpha 0.83–0.93; test‐retest ICC 0.88–0.92). Validity was supported by the interscale correlations (r = 0.47–0.59), known group differences, and the magnitude and pattern of correlations with four other rating scales, disease severity, and disease duration. In conclusion, the patient‐rated MSA health‐related Quality of life scale (MSA‐QoL) may be a suitable patient‐reported scale for use in clinical trials and studies in MSA. © 2007 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000976 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000976 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:CA7D73FBEAA9D591B85A840BC0BD145CC9A7B991
|texte= Measuring health‐related quality of life in MSA: The MSA‐QoL
}}
| This area was generated with Dilib version V0.6.23. |  |